surgical treatmentsGastroesophageal reflux disease (GERD) is the most prevalent foregut disease in the Western population, affecting roughly 15 million, or 6%, of the adult US population on a daily basis. Historically, laparoscopic fundoplication has been the primary treatment that addresses the ...
The new CSR ofEndoluminal Treatments for Gastroesophageal Reflux Disease (GERD),published online, reviews existing data and provides evidence-based answers to key clinically relevant questions. Developed by the SAGES Guidelines Committee, the CSR details outcomes of Stretta as compared to medications or ...
Targeted treatments for rheumatoid arthritis, Novel treatment strategies in rheumatoid arthritis, Gerd R Burmester, Janet E Pope; Adelphi RA DSP 2016 3. October 07, 2020, https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30229-0/fulltext 98 Daprodustat (HIF-PHI): potential...
because this is best done by experts in a therapeutic area. Similarly, we do not discuss drug pricing for novel treatments. Such discussion can only be meaningful based on input from experts within a specific therapeutic area who can judge on the added...
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a fi...
Although this is the first study to report this finding, the results support recent research reporting an increased incidence of dementia and GERD, which Dr. Adewuyi said could help with earlier diagnoses and potential treatments. “GERD may be a risk factor for cognitive impairment, so it’s...
A multiprofessional approach is recommended for rehabilitation of pain patients with comorbidities (Gerdle et al.,Citation2022; Scascighini et al.,Citation2008). However, the accessibility to interdisciplinary pain treatments varies due to economic, geographic, and organizational factors (Eklund et al....
Vorgerd, K. Gempel, K.D. Gerbitz, M.W. Kilimann Carnitine transporter OCTN2 mutations in systemic primary carnitine deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter mutation associated with an unconventional splicing abnormality Biochem. Biophys. Res. Commun., 261 (1999), pp...
Second, we suggest expanding the range and targets of treatments and prevention efforts beyond current practice guidelines for evidence-based interventions. This broader suite of interventions includes structural- and system-level change focused at community and societal levels (e.g., evidence-based ...
for up to 5% of objective halitosis complaints.31A systematic review investigated the relationship between GERD and halitosis (among other things). Three studies were included, and the authors concluded halitosis is a possible extra-oesophageal symptom of GERD,73however, two of these studies utilised...